Prevnar 13 (Pfizer) Drug Report 2018 - Despite a Slight Drop in US Sales from $3.6Bn in 2016 to $3.4Bn in 2017, Prevnar 13 Maintains a Dominant Hold on the Pneumococcal Vaccine Market - Financialbuzz.com
Prevnar 13 (Pfizer) Drug Report 2018 - Despite a Slight Drop in US Sales from $3.6Bn in 2016 to $3.4Bn in 2017, Prevnar 13 Maintains a Dominant Hold on the Pneumococcal Vaccine Market Financialbuzz.com
Dublin, June 27, 2019 (GLOBE NEWSWIRE) — The “Prevnar 13” report has been added to ResearchAndMarkets.com's offering. Prevnar 13 (13-valent ...
Comments
Post a Comment